Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

iRhythm Technologies, Inc. - Common Stock (NQ:IRTC)

187.30 +3.18 (+1.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about iRhythm Technologies, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
3 Healthcare Stocks in the Doghouse
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory... 
Via StockStory
Topics Stocks
Patient Monitoring Stocks Q4 In Review: Insulet (NASDAQ:PODD) Vs Peers
Let’s dig into the relative performance of Insulet (NASDAQ:PODD) and its peers as we unravel the now-completed Q4 patient monitoring earnings season. 
Via StockStory
Topics Artificial Intelligence
Patient Monitoring Stocks Q4 Results: Benchmarking ResMed (NYSE:RMD)
The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current business environment. Let’s take a look at how ResMed (NYSE:RMD) and the rest... 
Via StockStory
Topics Artificial Intelligence
Why Dexcom Is On A Six-Day Losing Spree — But This Analyst Isn't Worried
The company is facing a regulatory setback. But one analyst doesn't expect that to impact its upcoming, potential approval. 
Via Investor's Business Daily
Breaking Down iRhythm Technologies: 6 Analysts Share Their Views
 
Via Benzinga
Earnings Scheduled For February 20, 2025
 
Via Benzinga
Critical Insights From iRhythm Technologies Analyst Ratings: What You Need To Know
 
Via Benzinga
1 Growth Stock to Target This Week and 2 to Ignore
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
Reflecting On Patient Monitoring Stocks’ Q4 Earnings: DexCom (NASDAQ:DXCM)
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how patient monitoring stocks fared in Q4, starting with DexCom... 
Via StockStory
Topics Artificial Intelligence
iRhythm (NASDAQ:IRTC) Reports Strong Q4, Stock Soars
Medical technology company iRhythm Technologies (NASDAQ:IRTC) reported Q4 CY2024 results topping the market’s revenue expectations, with sales up 24% year on year to $164.3 million. The company expects... 
Via StockStory
iRhythm Technologies Announces Fourth Quarter and Full Year 2024 Financial Results
From iRhythm
Via GlobeNewswire
Forecasting The Future: 6 Analyst Projections For iRhythm Technologies
 
Via Benzinga
Earnings Preview For iRhythm Technologies
 
Via Benzinga
iRhythm (IRTC) To Report Earnings Tomorrow: Here Is What To Expect
Medical technology company iRhythm Technologies (NASDAQ:IRTC) will be announcing earnings results tomorrow afternoon. Here’s what investors should know. 
Via StockStory
iRhythm Technologies to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025
From iRhythm
Via GlobeNewswire
iRhythm Technologies Shares Preliminary Fourth Quarter 2024 Highlights and Business Update at the 43rd Annual J.P. Morgan Healthcare Conference
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Present at the 43rd Annual J.P. Morgan Healthcare Conference
From iRhythm
Via GlobeNewswire
Top 3 Robotics and Automation Stocks for the Next AI Boom
The next wave of AI will include interactive and autonomous AI and these three companies are making inroads into these areas today 
Via MarketBeat
Topics Artificial Intelligence
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukos
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges. 
Via Benzinga
iRhythm Technologies to Participate in the Citi 2024 Global Healthcare Conference
From iRhythm
Via GlobeNewswire
iRhythm Data Presented at the American Heart Association 2024 Scientific Sessions Reinforce Clinical and Health Economic Value of Zio Long-Term Continuous Monitoring
Five new studies span three focus areas for LTCM devices: digital engagement and patient satisfaction, arrhythmia patterns during sleep and activity, and the potential health care resource and economic... 
From iRhythm
Via GlobeNewswire
iRhythm Technologies to Participate in the Wolfe Research 2024 Healthcare Conference
From iRhythm
Via GlobeNewswire
IRHYTHM ALERT: Bragar Eagel & Squire, P.C. is Investigating iRhythm Technologies, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
iRhythm Technologies Receives FDA 510(k) Clearance for Design Modifications to Its Zio® AT Device
From iRhythm
Via GlobeNewswire
iRhythm Technologies Announces Third Quarter 2024 Financial Results
From iRhythm
Via GlobeNewswire
Newly Published Research Shows 14-Day Monitoring Detected Almost Three Times More Nonsustained Ventricular Tachycardia Than Standard 48-Hour Monitoring in Patients with Hypertrophic Cardiomyopathy
From iRhythm
Via GlobeNewswire
Trump Media & Tech, ImmunityBio, And iRhythm Are Among Top 10 Mid Cap Gainers Last Week (Oct 21-Oct 25): Are The Others In Your Portfolio?
These ten mid-cap stocks were the best performers in the last week. Are they in your portfolio? 
Via Benzinga
Topics Government
IRHYTHM INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of iRhythm Technologies, Inc. - IRTC
From Kahn Swick & Foti, LLC
Via Business Wire
Nasdaq Turns Higher; Verizon Shares Fall After Q3 Results
 
Via Benzinga
With FDA Approval iRhythm May Be Able To Lift Regulatory Overhang, Investor Skepticism, Analyst Says
FDA approves iRhythm's 510(k) submission for Zio AT device. A second approval may come soon, enhancing the company's mobile cardiac telemetry services. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.